Logo

Stelara® Delivers Rapid Efficacy In UC

In UC, STELARA® Delivers... Efficacy From A Single Iv Dose

1 Dose of STELARA® reduced the symptoms† of UC as early as Week 22

group-32x-

† Week 2, the earliest scheduled study visit, and at each visit thereafter during UNIFI induction study.
‡ Symptomatic remission is defined as a Mayo stool frequency sub-score of 0 or 1 and a rectal bleeding sub-score of 0.

~87% Of Biologic Non-Failure Patients Achieved Clinical Response With STELARA® At Either Week 8 Or 16 [3]

group_242x.png

§ 93.4% biologic naive.
¶ Decrease from induction baseline in Mayo score (stool frequency, rectal bleeding, finding on flexible proctosigmoidoscopy and physician's global assessment) by >30% and >3 points, with either a decrease from induction baseline in rectal bleeding sub-score of 0 or 1.
** Clinical response at either Week 8 or Week 16. Patients not in clinical response at Week 8 received STELARA® 90 mg SC at Week 8 (as per recommended product dosing) and were re-analysed for clinical response at Week 16. Patients were counted only once if they achieved response at Weeks 8 and 16.

Component not published? componentType is undefined.

Component not published? componentType is undefined.

* Long-term remission is considered a target of ideal treatment in the clinical management of ulcerative colitis (UC).[1]
IV: Intravenous; UC: Ulcerative colitis; SC: Subcutaneous.

Prescribing Information

Adverse Events Reporting

References

Danese S et al. Dig Dis 2019;37:266-283.
STELARA® 130 mg concentrate solution for infusion. 90 mg / 45 mg solution for injection. Summary of Product Characteristics. February 2020.
Danese S, et al. DOP54 presented at European Crohn’s and Colitis Organisation (ECCO) 14th Congress, 6–9 March 2019, Copenhagen, Denmark.
Danese S et al. Poster Tu1739 presented at Digestive Disease Week (DDW) Annual Meeting, 18–21 May 2019, San Diego, CA, USA.